1. Scrip
  2. >>Business

Teijin to launch home healthcare business in Europe

 
• By Zoë Dann

The Japanese company Teijin Pharma has established a 50:50 joint venture with the Spanish pharma company Laboratorios del Dr Esteve, to enter the home respiratory therapy market in Europe, beginning in Spain. The joint venture, Esteve Teijin Healthcare (ETH), will be established through Teijin's holding company in Europe, Teijin Holdings Netherlands. ETH will acquire Esteve's total stake in Oximeplus, a Spanish provider of home respiratory therapy services, accounting for 51% of the company's outstanding stock. The company is expected to be established by the end of January.

The Japanese company Teijin Pharma has established a 50:50 joint venture with the Spanish pharma company Laboratorios del Dr Esteve, to enter the home respiratory therapy market in Europe, beginning in Spain. The joint venture, Esteve Teijin Healthcare (ETH), will be established through Teijin's holding company in Europe, Teijin Holdings Netherlands. ETH will acquire Esteve's total stake in Oximeplus, a Spanish provider of home respiratory therapy services, accounting for 51% of the company's outstanding stock. The company is expected to be established by the end of January.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines

 
• By Mandy Jackson

Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.